Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by JDavenporton Dec 13, 2022 7:49pm
313 Views
Post# 35169839

Here's the bottom line.

Here's the bottom line.Bioasis, with a market cap tonight of CDN $11.5 million, is being bought by a company that goes to bed tonight with a market cap of only about CDN $6 million, and Bioasis shareholders end up with less than 10% of the resulting company.

Together, current Midatech and Bioasis shareholders will end up with less than 50% of the resulting company, meaning that control of the resulting company goes, it appears, to investors brought to the table by Ladenburg Thalmann.

The resulting company can do anything it wants without a single vote from current Midatech and Bioasis shareholders, including selling the company to private concerns, or selling xB3 to private concerns and running the Midatech/Bioasis combination on Cresence EGF stuff.

It looks to me like the current Midatech shareholders are just about as exposed as Bioasis shareholders are.

jd
<< Previous
Bullboard Posts
Next >>